Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Orion

48.72

 

EUR

 

+1.63 %

13,962 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
+1.63%
-10.77%
+9.26%
+13.88%
+1.27%
+47.64%
+15.81%
+20.74%
+333.84%

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
6.88B EUR
Turnover
2.81M EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Reduce
Target price
Updated
26.02.2025
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%
1.91.90.90.90032.823.127.025.833.027.022222323242425e25e26e26e27e27e

Revenue B

EBIT-% (adj.)

EPS and dividend
3.53.51.81.8003.24.33.63.53.63.722222323242425e25e26e26e27e27e

EPS (adj.)

Dividend %

Financial calendar
23.4.
2025

Interim report Q1'25

18.7.
2025

Interim report Q2'25

15.10.
2025

Half year dividend

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release4/10/2025, 10:15 AM

The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence

Orion
Press release4/9/2025, 10:30 AM

Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025

Orion
Regulatory press release4/3/2025, 1:25 PM

Orion Corporation: Organising meeting of the Board of Directors

Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release4/3/2025, 1:20 PM

Decisions taken by Orion Corporation’s Annual General Meeting on 3 April 2025

Orion
Orion, Webcast with teleconference, Q1'25
Webcast4/23/2025, 10:30 AM

Orion, Webcast with teleconference, Q1'25

Orion
Regulatory press release3/21/2025, 1:00 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Press release3/21/2025, 11:00 AM

Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030

Orion
Regulatory press release3/20/2025, 1:30 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release3/19/2025, 12:30 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release3/17/2025, 3:15 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release3/14/2025, 1:30 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release3/13/2025, 2:45 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release3/12/2025, 2:15 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release3/11/2025, 9:15 AM

Orion Group Financial Statement documents 2024 and Remuneration Report published

Orion
Regulatory press release3/11/2025, 7:00 AM

Orion Corporation: Managers’ transactions – Julia Macharey

Orion
Regulatory press release3/11/2025, 7:00 AM

Orion Corporation: Managers’ transactions – René Lindell

Orion
Regulatory press release3/11/2025, 7:00 AM

Orion Corporation: Managers’ transactions – Olli Huotari

Orion
Regulatory press release3/11/2025, 7:00 AM

Orion Corporation: Managers’ transactions – Hao Pan

Orion
Regulatory press release3/11/2025, 7:00 AM

Orion Corporation: Managers’ transactions – Niclas Lindstedt

Orion
Regulatory press release3/11/2025, 7:00 AM

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion
Forum discussions
Tässä vielä Liisa Hurmeen haastattelu ja aiheet alla kellotettuna. Koen vihdoin tuntevani Orionin sillä tasolla, että jätin tässäkin haastattelussa muistiinpanot pois mikä johti pariin extrarönsyilevään kysymykseen. Inderes Orion Q4’24: Nubeqasta “Blockbuster”-lääke - Inderes Aika...
2/25/2025, 2:00 PM
by Verneri Pulkkinen
17
Uusi tutkimus- ja tuotekehityskeskus Cambridgeen: Inderes Orion avaa uuden biologisten lääkkeiden T&K-keskuksen Cambridgeen vuonna... ORION OYJ LEHDISTÖTIEDOTE 10.3.2025 KLO 11.45 Orion avaa uuden biologisten lääkkeiden T&K-keskuksen Cambridgeen vuonna 2025 tukemaan globaalia kasvustrategi...
3/10/2025, 10:11 AM
by Ilkka
14
Suomessa keksitty lääke valloittaa maailmaa – Yhtiön kurssi nousussa Orionin Nubeqa-syöpälääkkeellä on myyntilupa jo 85 maassa. Lääkeyhtiö Orionin pörssikurssi on ollut vajaan vuoden verran tuhdissa nousussa. Orionin B-osake on kiivennyt viime huhtikuun puolivälin noin 33 eurosta...
3/2/2025, 1:40 PM
by Dissidentti
14
Tänään on vihdoin myös Bayerin tulos ulkona, joten pari huomioita Nubeqasta: Ensimmäinen huomio on, että Orionin raportoimat Nubeqan rojaltit Q4 olivat yllättävän korkeat suhteessa Bayerin vastaavaan Q4 myyntiin, joka on sekä posi (hyvä rojalti %) että nega uutinen (ei huimaa myynti...
3/5/2025, 4:30 PM
by Olliboi
13
Trump töräytti viime yönä lääketulleista, että ”tulossa ovat ja pian”. Taso olisi ”merkittävä”. https://www.reuters.com/world/us/trump-says-us-will-soon-announce-tariffs-pharmaceutical-imports-2025-04-09/
4/9/2025, 4:04 AM
by PörssiPatruuna
9
Tässä on herra Siltasen yhtiöraportti Orionista heti Q4:n jälkeen. Orionin vahvat liikevaihto ja -tulos olivat tiedossa jo ennalta tammikuisen näkymien noston jäljiltä. Kasvun taustalla oli useita tekijöitä, mutta merkittävin ajuri oli totutusti Nubeqa, jonka myynti on kiihdyttänyt...
2/26/2025, 5:57 AM
by Sijoittaja-alokas
8
Toimitusjohtaja Liisa Hurmeen katsaus tämän kevään yhtiökokouksesta! Inderes Orionin yhtiökokous | Toimitusjohtajan katsaus 3.4.2025 - Inderes Aika: 14.04.2025 klo 12.54 Toimitusjohtaja Liisa Hurmeen katsaus Orionin yhtiökokouksesta 3.4.2025.
4 hours ago
by Sara Antonacci
7
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.